



05/07/97

PATENT
Atty. Docket No. SYP-116
(7783/109)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): FUCHS et al.

SERIAL NUMBER: 08/726,093

GROUP No.: 1816


FILING DATE: October 4, 1996

EXAMINER:

TITLE: METHODS AND KIT FOR HYBRIDIZATION ANALYSIS USING
PEPTIDE NUCLEIC ACID PROBES

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any documents referred to as enclosed therein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Box Sequence, Assistant Commissioner for Patents, Washington, DC 20231 on 5/14/97.


Betty B. Leveriza

Box Sequence

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

**SUBMISSION OF "SEQUENCE LISTING", COMPUTER READABLE COPY, AND/OR
AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE**

(check and complete this item, if applicable)

1. ☐ This replies to the Office Letter dated

Note: If these papers are filed before the office letter issues adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the serial number from the return post card or the attorney's docket number added.

- ☐ A copy of the Office Letter is enclosed.

IDENTIFICATION OF DECLARANT

Submission Of "Sequence Listing", Computer Readable Copy, And/Or Amendment Pertaining
Thereto For Biotechnology Invention Containing Nucleotide And/Or Amino Acid Sequence
Page 2

2. I Thomas A. Turano

(Type or print name of declarant signing below)
state the following:

3. Submitted herewith is/are

(check each item as applicable)

- A. ☒ "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application, each "Sequence Listing" is assigned a separate identifier as required in 37 CFR §1.821(c) and 37 CFR §§1.822 and 1.823
- B. ☒ An amendment to the description and/or claims wherein reference is made to the sequence by use of the assigned identifier as required in 37 CFR §1.821(d)
- C. ☒ A copy of **each** "Sequence Listing" submitted for this application in computer readable form in accordance with the requirements of 37 CFR §§1.821(e) and 1.824
- D. ☐ Please transfer to this application, in accordance with 37 CFR §1.821(e), the computer readable copy(ies) from applicant's **other** application identified as follows:

APPLICANT(S):

SERIAL NO.: _____

GROUP NO.: _____

FILED: _____

EXAMINER: _____

TITLE:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form
(other application)

"Sequence Identifier"
(this application)

Note: If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference may be made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified.
37 CFR 1.821(e).

- E. ☒ A statement that the content of **each** "Sequence Listing" submitted and **each** computer readable copy are the same as required in 37 CFR §1.821(f).

☐ Since the statement is **not** made by a person registered to practice before the Office the Statement is verified as required in 37 CFR §1.821(f)

F. ☒ Since this submission is made in fulfilling the requirement under 37 CFR §1.821(f), a statement that the submission includes no new matter

☐ Since the statement is **not** made by a person registered to practice before the Office the statement is verified as required in 37 CFR §1.821(f)

**STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY
ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW
MATTER**

4. I hereby state:

(complete applicable item A and/or B)

- A. ☒ Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. ☒ All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

VERIFICATION

5. Note: "Such a statement must be verified statement if made by a person not registered to practice before the Office." 37 CFR §1.821(f) and (g).

☐ I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

STATUS

6. Applicant is

☐ a small entity--verified statement:

☐ attached.

☐ already filed.

☒ other than a small entity.

EXTENSION OF TERM

7. Note: "Extension of Time in Patent Cases (Supplement Amendments)--if a timely and complete response has been filed after a Non-Final office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of December 10, 1985 (1061 O.G. 34-35).

NOTED: See 37 CFR 1.645 for extensions of time in interference proceedings and 37 CFR 1.550(c) for extensions of time in reexamination proceedings.

8. The proceedings herein are for a patent application and the provisions of 37 CFR 1.136 apply

(complete (a) or (b) as applicable)

- (a) ☐ Applicant petitions for an extension of time under 37 CFR 1.136 (fees: 37 CFR 1.17(a)-(d) for the total number of months checked below:

	Extension (months)	Fee for other than Small Entity	Fee for Small Entity
<input type="checkbox"/>	one month	\$ 110.00	\$ 55.00
<input type="checkbox"/>	two months	\$ 390.00	\$195.00
<input type="checkbox"/>	three months	\$ 930.00	\$465.00
<input type="checkbox"/>	four months	\$1,470.00	\$735.00

Fee \$

If an additional extension of time is required please consider this a petition therefor.

(check and complete the next item, if applicable)

- ☐ An extension for _____ months has already been secured and the fee paid therefor of \$ _____ is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$

or

- (b) ☐ Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

FEE PAYMENT

9. ☐ Attached is a check in the sum of \$ ____.
- ☐ Charge Account No. 20-0531 the sum of \$ ____.

A duplicate of this transmittal is attached.

FEE DEFICIENCY

10. Note: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO Finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the **Notice of April 7, 1986**, 1065 O.G. 31-33.

11. ☒ If any additional extension and/or fee is required, charge Account No. 20-0531.

Type or print name of person signing declaration

Date

Signature

P.O. Address of Signatory

- ☐ Inventor
☐ Assignee of complete interest
☐ Person authorized to sign on behalf of assignee
☐ Attorney or agent of record
☐ Filed under Rule 34 (a)
☐ Other:

Tel. No.:

Reg. No.
(if applicable)

(Specify identify of declarant)

(Complete the following if applicable)

Submission Of "Sequence Listing", Computer Readable Copy, And/Or Amendment Pertaining
Thereto For Biotechnology Invention Containing Nucleotide And/Or Amino Acid Sequence
Page 6

PerSeptive Biosystems, Inc.

Type name of assignee

500 Old Connecticut Path Road, Framingham, MA 01701

Address of assignee

Title of person authorized to sign on behalf of assignee

Assignment submitted to the PTO Assignment branch on March 10, 1997

Reel _____ Frame

(If the person signing above is not an attorney registered
to practice before the Office complete the following)

Date: 5/10/87

Reg. No. 35,722

Tel. No. (617) 248-7738

Fax: (617) 248-7100

Thomas A. Turano

Attorney for Applicants

Testa, Hurwitz, & Thibault, LLP

High Street Tower

125 High Street

Boston, Massachusetts 02110